Cargando…
Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip
Past studies on the protective effects of chitosan oligosaccharides (COS) on inflammatory bowel disease (IBD) commonly rely on animal models, because traditional cell culture systems couldn’t faithfully mimic human intestinal physiology. Here a novel human gut-on-a-chip microsystem was established t...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086312/ https://www.ncbi.nlm.nih.gov/pubmed/35557948 http://dx.doi.org/10.3389/fcell.2022.877892 |
_version_ | 1784703969947287552 |
---|---|
author | Jing, Bolin Xia, Kun Zhang, Chen Jiao, Siming Zhu, Limeng Wei, Jinhua Wang, Zhuo A. Chen, Nannan Tu, Pengfei Li, Jianjun Du, Yuguang |
author_facet | Jing, Bolin Xia, Kun Zhang, Chen Jiao, Siming Zhu, Limeng Wei, Jinhua Wang, Zhuo A. Chen, Nannan Tu, Pengfei Li, Jianjun Du, Yuguang |
author_sort | Jing, Bolin |
collection | PubMed |
description | Past studies on the protective effects of chitosan oligosaccharides (COS) on inflammatory bowel disease (IBD) commonly rely on animal models, because traditional cell culture systems couldn’t faithfully mimic human intestinal physiology. Here a novel human gut-on-a-chip microsystem was established to further explore the regulatory effects of COS on the occurrence and development of human enteritis. By constructing an intestinal injury model caused by dextran sodium sulfate (DSS) on the chip, this study proved that COS can reduce intestinal epithelial injury by promoting the expression of the mucous layer for the first time. By establishing an inflammatory bowel disease model on the chip caused by E. coli 11775, this study demonstrated that COS can protect the intestinal epithelial barrier and vascular endothelial barrier by inhibiting the adhesion and invasion of E. coli 11775 for the first time. In addition, similar to the results in vivo, COS can decrease the inflammatory response by reducing the expression of toll-like receptor 4 protein and reducing the nuclear DNA binding rate of nuclear factor kappa-B protein on this chip. In summary, COS can be used as a potential drug to treat human IBD and the human gut-on-a-chip would be used as a platform for quick screening drugs to treat human IBD in future. |
format | Online Article Text |
id | pubmed-9086312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90863122022-05-11 Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip Jing, Bolin Xia, Kun Zhang, Chen Jiao, Siming Zhu, Limeng Wei, Jinhua Wang, Zhuo A. Chen, Nannan Tu, Pengfei Li, Jianjun Du, Yuguang Front Cell Dev Biol Cell and Developmental Biology Past studies on the protective effects of chitosan oligosaccharides (COS) on inflammatory bowel disease (IBD) commonly rely on animal models, because traditional cell culture systems couldn’t faithfully mimic human intestinal physiology. Here a novel human gut-on-a-chip microsystem was established to further explore the regulatory effects of COS on the occurrence and development of human enteritis. By constructing an intestinal injury model caused by dextran sodium sulfate (DSS) on the chip, this study proved that COS can reduce intestinal epithelial injury by promoting the expression of the mucous layer for the first time. By establishing an inflammatory bowel disease model on the chip caused by E. coli 11775, this study demonstrated that COS can protect the intestinal epithelial barrier and vascular endothelial barrier by inhibiting the adhesion and invasion of E. coli 11775 for the first time. In addition, similar to the results in vivo, COS can decrease the inflammatory response by reducing the expression of toll-like receptor 4 protein and reducing the nuclear DNA binding rate of nuclear factor kappa-B protein on this chip. In summary, COS can be used as a potential drug to treat human IBD and the human gut-on-a-chip would be used as a platform for quick screening drugs to treat human IBD in future. Frontiers Media S.A. 2022-04-26 /pmc/articles/PMC9086312/ /pubmed/35557948 http://dx.doi.org/10.3389/fcell.2022.877892 Text en Copyright © 2022 Jing, Xia, Zhang, Jiao, Zhu, Wei, Wang, Chen, Tu, Li and Du. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Jing, Bolin Xia, Kun Zhang, Chen Jiao, Siming Zhu, Limeng Wei, Jinhua Wang, Zhuo A. Chen, Nannan Tu, Pengfei Li, Jianjun Du, Yuguang Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip |
title | Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip |
title_full | Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip |
title_fullStr | Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip |
title_full_unstemmed | Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip |
title_short | Chitosan Oligosaccharides Regulate the Occurrence and Development of Enteritis in a Human Gut-On-a-Chip |
title_sort | chitosan oligosaccharides regulate the occurrence and development of enteritis in a human gut-on-a-chip |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086312/ https://www.ncbi.nlm.nih.gov/pubmed/35557948 http://dx.doi.org/10.3389/fcell.2022.877892 |
work_keys_str_mv | AT jingbolin chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip AT xiakun chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip AT zhangchen chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip AT jiaosiming chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip AT zhulimeng chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip AT weijinhua chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip AT wangzhuoa chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip AT chennannan chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip AT tupengfei chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip AT lijianjun chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip AT duyuguang chitosanoligosaccharidesregulatetheoccurrenceanddevelopmentofenteritisinahumangutonachip |